SCHEMBL1732835

SCHEMBL1732835

CCCCC[C@H](Br)C(=O)O

nearest known ligand 0.95

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.95
PPARD Q03181 1/20 0.95
ZDHHC20 Q5W0Z9 1/20 0.95
ZDHHC2 Q9UIJ5 1/20 0.95
ZDHHC7 Q9NXF8 1/20 0.59
GPR84 Q9NQS5 7/20 0.56
FFAR1 O14842 1/20 0.56
MAPT P10636 1/20 0.54
ACE2 Q9BYF1 1/20 0.50
GRIK1 P39086 2/20 0.47
GRIK2 Q13002 2/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
CA2 P00918 1/20 0.46
MAPK1 P28482 1/20 0.46
FFAR4 Q5NUL3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1732565 1.00 LCK (0.95) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL1036505 1.00 LCK (0.95) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL338250 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL2721068 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL337479 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL23829555 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL10595854 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL375050 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL3790420 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7
SCHEMBL338237 0.98 LCK (1.00) LCKPPARDZDHHC20ZDHHC2ZDHHC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8540966-B2 Contrast agents endowed with high relaxivity BRACCO IMAGING S.P.A. (IT) 2013-09-24 US disclosed
US-8105567-B2 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING SPA (IT) 2012-01-31 US disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
US-20110256067-A1 Contrast agents endowed with high relaxivity BRACCO IMAGING SPA (IT) 2011-10-20 US disclosed
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules BRACCO IMAGING S.P.A. (IT) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110256067-A1 Contrast agents endowed with high relaxivity SLC40A1, SLC67A1, SLC19A1 LCK 4800/4885PPARD 3523/4885ZDHHC20 3733/4885
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules CD99, CD209, PRMT9 LCK 657/4885PPARD 3636/4885ZDHHC20 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.